Clinical Trials Logo

Clinical Trial Summary

Thoracic aortic aneurysms (TAA) are considered "silent killers" because they scarcely display any symptomatology, but are correlated with significant mortality and morbidity. Current guidelines regard aortic aneurysm disease as a coronary artery disease equivalent and suggest aspirin and statin use to reduce the progression of atherosclerosis, as well as beta-blocker (BB) therapy. No therapy, however, is effective at limiting aneurysm expansion and preventing rupture, even in large trials. TAA has emerged as an inflammation-mediated disorder. Angiotensin-converting enzyme inhibitors (ACEIs) can reduce the wall shear stress and inflammation, both of which play vital roles in the expansion of the aneurysm.

The study will be a randomized, double-blind trial. Patients will be randomized into one of two parallel arms, receiving captopril or atenolol. The doses of captopril and atenolol will be 25 mg daily for the first 15 days, rising to 100 mg according to clinical tolerance and BP estimates. The sample size will be set at 424 subjects (212 per group). The primary end-point will be the rate of change in the absolute diameter of the aortic root and ascending aorta on MRI of the aorta after 36 months of therapy with captopril vs. atenolol.

BBs have not been precisely found to decrease aneurysm growth rates. ACEIs could lead to the prevention of aneurysm degeneration through their antihypertensive and anti-inflammatory properties.

The results of this trial will clarify that ACEIs are superior to BB therapy in reducing the growth rate of TAAs, the rate of change in aortic insufficiency, the time to aortic rupture or dissection, the need for aortic surgery or intervention, and death.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04224675
Study type Interventional
Source Onassis Cardiac Surgery Centre
Contact
Status Not yet recruiting
Phase N/A
Start date March 7, 2020
Completion date March 7, 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06235619 - Arch Size Study for Anatomical Variations
Completed NCT01178710 - Effect of Simvastatin on Cardiac Function N/A
Not yet recruiting NCT00905931 - Lycopene Following Aneurysmal Subarachnoid Haemorrhage Phase 2
Completed NCT00349908 - A Feasibility Study of the Cordis Neurovascular Self Expanding Stent System in Intracranial Arteries Phase 1
Recruiting NCT03285100 - The Effects of Discontinuation of Vitamin K Antagonists on the Rate of Elastin Degradation N/A
Recruiting NCT06189950 - Registration Trial of the Intracranial Visualized Stent for the Wide-necked Intracranial Aneurysms:REBRIDGE N/A
Active, not recruiting NCT04592185 - The Study of the Fenestrated Anaconda Device in the Treatment of Abdominal Aortic Aneurysms
Completed NCT01970605 - Silver Graft All Comers Registry
Completed NCT00282893 - Balloon Prophylaxis of Aneurysmal Vasospasm Phase 2
Active, not recruiting NCT00549380 - Clinical Study of Aneurysm Exclusion Phase 1
Completed NCT04598802 - COvera in BRAnch Registry
Completed NCT04246125 - Patient Skin Dose in Interventional Radiology
Recruiting NCT05829746 - PROSPECTIVE, MULTI-CENTER, OPEN-LABEL, SINGLE-ARM REGISTRATION TRIAL OF THE TUBRIDGE FOR THE TREATMENT OF WIDE-NECKED SMALL AND MEDIUM-SIZED INTRACRANIAL ANEURYSMS N/A
Completed NCT03242343 - VasQ External Support for Arteriovenous Fistula N/A
Recruiting NCT02878967 - Standardized Long Term Follow-up of Patients After Endovascular Embolization of a Brain Aneurysm
Active, not recruiting NCT02345005 - Iliac Branch Excluder ReGistry (IceBERG)
Recruiting NCT02167997 - EffectiveNess and SAfety of Small ANeurysm COiling Trial N/A
Recruiting NCT00549016 - Clinical Study of Aneurysm Exclusion N/A
Completed NCT02848612 - Evaluation of the Amiens University Hospital Neuroradiology Anticoagulation Protocol
Enrolling by invitation NCT04269447 - Prospective Aortic Biobank of POP-STAR